|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CPE |
Gene summary for CPE |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CPE | Gene ID | 1363 |
| Gene name | carboxypeptidase E | |
| Gene Alias | CPH | |
| Cytomap | 4q32.3 | |
| Gene Type | protein-coding | GO ID | GO:0003007 | UniProtAcc | P16870 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1363 | CPE | CA_HPV_3 | Human | Cervix | CC | 8.55e-36 | 5.94e-01 | 0.0414 |
| 1363 | CPE | sample1 | Human | Cervix | CC | 4.46e-16 | 6.90e-01 | 0.0959 |
| 1363 | CPE | T1 | Human | Cervix | CC | 4.63e-33 | 7.44e-01 | 0.0918 |
| 1363 | CPE | LZE24T | Human | Esophagus | ESCC | 2.55e-02 | -2.78e-01 | 0.0596 |
| 1363 | CPE | P2T-E | Human | Esophagus | ESCC | 2.69e-89 | 2.53e+00 | 0.1177 |
| 1363 | CPE | P4T-E | Human | Esophagus | ESCC | 1.66e-20 | 7.59e-01 | 0.1323 |
| 1363 | CPE | P10T-E | Human | Esophagus | ESCC | 4.97e-12 | 2.95e-01 | 0.116 |
| 1363 | CPE | P11T-E | Human | Esophagus | ESCC | 4.91e-03 | 4.69e-01 | 0.1426 |
| 1363 | CPE | P12T-E | Human | Esophagus | ESCC | 3.19e-03 | -2.42e-01 | 0.1122 |
| 1363 | CPE | P16T-E | Human | Esophagus | ESCC | 2.64e-43 | 1.19e+00 | 0.1153 |
| 1363 | CPE | P21T-E | Human | Esophagus | ESCC | 3.79e-04 | -1.37e-01 | 0.1617 |
| 1363 | CPE | P22T-E | Human | Esophagus | ESCC | 2.00e-17 | 4.87e-01 | 0.1236 |
| 1363 | CPE | P23T-E | Human | Esophagus | ESCC | 1.51e-03 | 4.76e-01 | 0.108 |
| 1363 | CPE | P26T-E | Human | Esophagus | ESCC | 3.48e-76 | 1.71e+00 | 0.1276 |
| 1363 | CPE | P28T-E | Human | Esophagus | ESCC | 7.36e-03 | -1.78e-01 | 0.1149 |
| 1363 | CPE | P31T-E | Human | Esophagus | ESCC | 6.04e-03 | -1.54e-01 | 0.1251 |
| 1363 | CPE | P32T-E | Human | Esophagus | ESCC | 1.57e-06 | 1.77e-01 | 0.1666 |
| 1363 | CPE | P37T-E | Human | Esophagus | ESCC | 9.84e-21 | 8.79e-01 | 0.1371 |
| 1363 | CPE | P39T-E | Human | Esophagus | ESCC | 3.49e-03 | -2.00e-01 | 0.0894 |
| 1363 | CPE | P40T-E | Human | Esophagus | ESCC | 2.89e-02 | 1.71e-01 | 0.109 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00712294 | Prostate | BPH | cellular response to acid chemical | 23/3107 | 80/18723 | 4.53e-03 | 2.19e-02 | 23 |
| GO:20007652 | Prostate | BPH | regulation of cytoplasmic translation | 7/3107 | 16/18723 | 9.80e-03 | 4.13e-02 | 7 |
| GO:00712303 | Prostate | BPH | cellular response to amino acid stimulus | 20/3107 | 71/18723 | 9.89e-03 | 4.16e-02 | 20 |
| GO:00435244 | Prostate | BPH | negative regulation of neuron apoptotic process | 35/3107 | 145/18723 | 1.23e-02 | 4.94e-02 | 35 |
| GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
| GO:000641719 | Prostate | Tumor | regulation of translation | 161/3246 | 468/18723 | 1.55e-19 | 8.74e-17 | 161 |
| GO:007149619 | Prostate | Tumor | cellular response to external stimulus | 103/3246 | 320/18723 | 5.29e-11 | 3.41e-09 | 103 |
| GO:001605514 | Prostate | Tumor | Wnt signaling pathway | 131/3246 | 444/18723 | 1.16e-10 | 7.11e-09 | 131 |
| GO:019873814 | Prostate | Tumor | cell-cell signaling by wnt | 131/3246 | 446/18723 | 1.61e-10 | 9.69e-09 | 131 |
| GO:007048218 | Prostate | Tumor | response to oxygen levels | 102/3246 | 347/18723 | 1.62e-08 | 5.75e-07 | 102 |
| GO:003166818 | Prostate | Tumor | cellular response to extracellular stimulus | 78/3246 | 246/18723 | 2.34e-08 | 8.08e-07 | 78 |
| GO:003629318 | Prostate | Tumor | response to decreased oxygen levels | 94/3246 | 322/18723 | 8.37e-08 | 2.29e-06 | 94 |
| GO:003166719 | Prostate | Tumor | response to nutrient levels | 127/3246 | 474/18723 | 1.27e-07 | 3.28e-06 | 127 |
| GO:003424912 | Prostate | Tumor | negative regulation of cellular amide metabolic process | 80/3246 | 273/18723 | 6.33e-07 | 1.32e-05 | 80 |
| GO:003166917 | Prostate | Tumor | cellular response to nutrient levels | 66/3246 | 215/18723 | 1.00e-06 | 1.94e-05 | 66 |
| GO:007099719 | Prostate | Tumor | neuron death | 98/3246 | 361/18723 | 1.81e-06 | 3.19e-05 | 98 |
| GO:001714812 | Prostate | Tumor | negative regulation of translation | 71/3246 | 245/18723 | 4.08e-06 | 6.51e-05 | 71 |
| GO:000926716 | Prostate | Tumor | cellular response to starvation | 50/3246 | 156/18723 | 5.17e-06 | 8.00e-05 | 50 |
| GO:005160415 | Prostate | Tumor | protein maturation | 81/3246 | 294/18723 | 7.58e-06 | 1.13e-04 | 81 |
| GO:190121419 | Prostate | Tumor | regulation of neuron death | 86/3246 | 319/18723 | 1.01e-05 | 1.46e-04 | 86 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0494016 | Cervix | CC | Type I diabetes mellitus | 17/1267 | 43/8465 | 7.47e-05 | 5.04e-04 | 2.98e-04 | 17 |
| hsa0494017 | Cervix | CC | Type I diabetes mellitus | 17/1267 | 43/8465 | 7.47e-05 | 5.04e-04 | 2.98e-04 | 17 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CPE | SNV | Missense_Mutation | c.739C>T | p.Leu247Phe | p.L247F | P16870 | protein_coding | tolerated(0.08) | benign(0.342) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| CPE | SNV | Missense_Mutation | c.448N>T | p.Arg150Cys | p.R150C | P16870 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| CPE | SNV | Missense_Mutation | c.376N>G | p.Phe126Val | p.F126V | P16870 | protein_coding | tolerated(0.3) | benign(0.021) | TCGA-C8-A12V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CPE | SNV | Missense_Mutation | c.731C>A | p.Ser244Tyr | p.S244Y | P16870 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A6DW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| CPE | SNV | Missense_Mutation | novel | c.274G>A | p.Glu92Lys | p.E92K | P16870 | protein_coding | deleterious(0) | benign(0.155) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CPE | SNV | Missense_Mutation | rs756392535 | c.566N>A | p.Arg189Gln | p.R189Q | P16870 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AA-3502-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CPE | SNV | Missense_Mutation | c.214G>A | p.Ala72Thr | p.A72T | P16870 | protein_coding | tolerated(0.28) | benign(0.007) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CPE | SNV | Missense_Mutation | novel | c.596N>G | p.Tyr199Cys | p.Y199C | P16870 | protein_coding | deleterious(0) | benign(0.359) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CPE | SNV | Missense_Mutation | rs753892074 | c.802N>A | p.Glu268Lys | p.E268K | P16870 | protein_coding | tolerated(0.22) | benign(0.298) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CPE | SNV | Missense_Mutation | c.449N>A | p.Arg150His | p.R150H | P16870 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |